BioNTech says aims to start building mRNA vaccine factory in Africa in mid-22

BioNTech on Tuesday said it had signed a Memorandum of Understanding with the Rwandan government and Institut Pasteur de Dakar in Senegal on the construction of a first mRNA vaccine manufacturing facility in Africa starting in mid-2022.

BioNTech on Tuesday said it had signed a Memorandum of Understanding with the Rwandan government and Institut Pasteur de Dakar in Senegal on the construction of a first mRNA vaccine manufacturing facility in Africa starting in mid-2022. BioNTech will initially build a production line with 50 million doses annual capacity, which could be used for COVID-19 vaccines, it said in a statement.

This will be branched out into a wider production network making several hundreds of million mRNA vaccine doses per year with the goal to transfer ownership and the know-how to local partners on the continent, the biotech firm added. Speaking at a media briefing in the Rwandan capital Kigali, European Union Commissioner for International Partnerships, Jutta Urpilainen, said that the initial site would be built in Rwanda.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)